Malignant Glioma
155
13
30
91
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
53 trials with published results (34%)
Research Maturity
91 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.0%
17 terminated out of 155 trials
84.3%
-2.3% vs benchmark
2%
3 trials in Phase 3/4
58%
53 of 91 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 91 completed trials
Clinical Trials (155)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
CARv3-TEAM-E T Cells in Glioblastoma
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
Fitness and Nutrition in Glioma
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
D2C7 for Adult Patients With Recurrent Malignant Glioma
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
D2C7-IT With Atezolizumab for Recurrent Gliomas
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)